Vorapaxar (Zontivity) was approved in the EU in March 2015 for the reduction of atherothrombotic events in adults with a history of myocardial infarction, in combination with aspirin and, where appropriate, clopidogrel. In June 2016, it received a positive opinion in the EU for a licence extension to also include patients with a history of symptomatic peripheral arterial disease. It has not yet been launched in UK.